{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T13:54:33Z","timestamp":1794664473976,"version":"4.9.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T00:00:00Z","timestamp":1734480000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>RelabotulinumtoxinA (RelaBoNT-A) is a complex-free, ready-to-use, liquid botulinum toxin A.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>Efficacy\/safety of RelaBoNT-A treatment for lateral canthal lines (LCL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS<\/jats:title>\n            <jats:p>Randomized adults received RelaBoNT-A (30 U\/side; <jats:italic toggle=\"yes\">n<\/jats:italic> = 230) or placebo (<jats:italic toggle=\"yes\">n<\/jats:italic> = 73) during a 6-month, double-blind, Ph3 study (Relabotulinumtoxin Aesthetic Development Study-2 [READY-2]). Primary end points (Month 1, maximum smile) comprised: composite \u22652-grade responder rate using concurrent LCL severity investigator live assessment (LCL-ILA) and subject live assessment (LCL-SLA); LCL-ILA 0 (none)\/1 (mild) responder rate. Subject satisfaction and adverse events were also reported.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Month 1 composite \u22652-grade responder rates were 51.8% (RelaBoNT-A) and 1.4% (placebo; (<jats:italic toggle=\"yes\">p<\/jats:italic> &lt; .001). Month 1 none\/mild LCL-ILA responder rates were 87.2% (RelaBoNT-A) and 11.9% (placebo; <jats:italic toggle=\"yes\">p<\/jats:italic> &lt; .001). Onset was reported Day 1 by 34%. At Month 6, LCL-ILA responder rates for RelaBoNT-A remained at 23.3% (none\/mild) and 35.9% (\u22651-grade improvement). Median return to baseline severity was 24.7 weeks; 64% (RelaBoNT-A group) had not returned to baseline at Month 6. RelaBoNT-A satisfaction was high through Month 6 (71%). Mild\/moderate treatment-related adverse events occurred in 6.1% (RelaBoNT-A) and 5.5% (placebo).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>RelaBoNT-A (60 U) treatment provided statistically significant improvement of moderate-to-severe LCL. One-third of subjects reported onset within 1 day and improvements were maintained through Month 6. Treatment satisfaction was high. RelaBoNT-A was well tolerated.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000004470","type":"journal-article","created":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T13:01:18Z","timestamp":1734526878000},"page":"277-283","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety of RelabotulinumtoxinA Liquid Botulinum Toxin in the Treatment of Lateral Canthal Lines: Results From the Phase 3 READY-2 Study"],"prefix":"10.1097","volume":"51","author":[{"given":"Glynis","family":"Ablon","sequence":"first","affiliation":[{"name":"Ablon Skin Institute and Research Center, Manhattan Beach, California ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bank","sequence":"additional","affiliation":[{"name":"The Center for Dermatology, Cosmetic & Laser Surgery, Mount Kisco, New York ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theda C.","family":"Kontis","sequence":"additional","affiliation":[{"name":"Facial Plastic Surgicenter, Baltimore, Maryland ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherrif F.","family":"Ibrahim","sequence":"additional","affiliation":[{"name":"Rochester Dermatologic Surgery, Victor, New York ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Palm","sequence":"additional","affiliation":[{"name":"Art of Skin MD, Solana Beach, California ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue Ellen","family":"Cox","sequence":"additional","affiliation":[{"name":"Aesthetic Solutions, Chapel Hill, North Carolina ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason K.","family":"Rivers","sequence":"additional","affiliation":[{"name":"Pacific Derm, Vancouver, British Columbia, Canada;"},{"name":"Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Grunebaum","sequence":"additional","affiliation":[{"name":"Siperstein Dermatology Group, Boynton Beach, Florida;"},{"name":"Division of Facial plastic and Reconstructive Surgery, Mayo Clinic, Phoenix, Arizona"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchel P.","family":"Goldman","sequence":"additional","affiliation":[{"name":"Cosmetic Laser Dermatology: A Platinum Dermatology Partners Company, San Diego, California ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Humphrey","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Science, University of British Columbia, Vancouver, British Columbia, Canada;"},{"name":"Humphrey Cosmetic Dermatology, Vancouver, British Columbia, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Coquis-Knezek","sequence":"additional","affiliation":[{"name":"Galderma, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,18]]},"reference":[{"key":"R1-20250228","doi-asserted-by":"crossref","first-page":"99","DOI":"10.4103\/jispcd.JISPCD_430_18","article-title":"Botulinum toxin application in facial esthetics and recent treatment indications (2013-2018)","volume":"9","author":"Kattimani","year":"2019","journal-title":"J Int Soc Prev Community Dent"},{"key":"R2-20250228","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1093\/asj\/sjw284","article-title":"AbobotulinumtoxinA: a 25-year history","volume":"37","author":"Monheit","year":"2017","journal-title":"Aesthet Surg J"},{"key":"R3-20250228","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/DSS.0000000000001679","article-title":"Efficacy, safety, and subject satisfaction after AbobotulinumtoxinA treatment of upper facial lines","volume":"44","author":"Hexsel","year":"2018","journal-title":"Dermatol Surg"},{"issue":"suppl 1","key":"R4-20250228","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1468-3083.2009.03475.x","article-title":"Treatment of glabellar lines with botulinum toxin type A (Speywood Unit): a clinical overview","volume":"24","author":"Rzany","year":"2010","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R5-20250228","doi-asserted-by":"crossref","first-page":"13S","DOI":"10.1177\/1090820X12474632","article-title":"A review of AbobotulinumtoxinA (dysport)","volume":"33","author":"Lorenc","year":"2013","journal-title":"Aesthet Surg J"},{"key":"R6-20250228","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7181\/acfs.2021.00003","article-title":"Scientific review of the aesthetic uses of botulinum toxin type A","volume":"22","author":"Park","year":"2021","journal-title":"Arch Craniofac Surg"},{"key":"R7-20250228","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s00266-021-02483-1","article-title":"Avoiding complications on the upper face treatment with botulinum toxin: a practical guide","volume":"46","author":"Borba","year":"2022","journal-title":"Aesthet Plast Surg"},{"key":"R8-20250228","doi-asserted-by":"crossref","first-page":"518e","DOI":"10.1097\/01.prs.0000475758.63709.23","article-title":"Global aesthetics consensus: botulinum toxin type A--evidence-based review, emerging concepts, and consensus recommendations for aesthetic use, including updates on complications","volume":"137","author":"Sundaram","year":"2016","journal-title":"Plast Reconstr Surg"},{"issue":"suppl 1","key":"R9-20250228","doi-asserted-by":"crossref","first-page":"S153","DOI":"10.1097\/DSS.0000000000000293","article-title":"Facial treatment preferences in aesthetically aware women","volume":"41","author":"Narurkar","year":"2015","journal-title":"Dermatol Surg"},{"key":"R10-20250228","doi-asserted-by":"crossref","first-page":"2692","DOI":"10.1111\/jocd.15768","article-title":"SAMCEP Society consensus on the treatment of upper facial lines with botulinum neurotoxin type A: a tailored approach","volume":"22","author":"Braccini","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"R11-20250228","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/DSS.0000000000000220","article-title":"Efficacy and safety of onabotulinumtoxinA for treating crow's feet lines alone or in combination with glabellar lines: a multicenter, randomized, controlled trial","volume":"41","author":"Moers-Carpi","year":"2015","journal-title":"Dermatol Surg"},{"issue":"suppl_1","key":"R12-20250228","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1093\/asj\/sjw282","article-title":"Key parameters for the use of abobotulinumtoxinA in aesthetics: onset and duration","volume":"37","author":"Nestor","year":"2017","journal-title":"Aesthet Surg J"},{"key":"R13-20250228","first-page":"E69","article-title":"Patient satisfaction with abobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review and post-hoc analysis of the APPEAL study","volume":"14","author":"Smit","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"R14-20250228","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1111\/jocd.15172","article-title":"Heterogeneous crow's feet line patterns and customized botulinum toxin rejuvenating treatment","volume":"21","author":"Cavallini","year":"2022","journal-title":"J Cosmet Dermatol"},{"key":"R15-20250228","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/DSS.0000000000000336","article-title":"Heterogeneity of crow's feet line patterns in clinical trial subjects","volume":"41","author":"Kane","year":"2015","journal-title":"Dermatol Surg"},{"key":"R16-20250228","first-page":"E56","article-title":"Onset and duration of AbobotulinumtoxinA for aesthetic use in the upper face: a systematic literature review","volume":"13","author":"Nestor","year":"2020","journal-title":"J Clin Aesthet Dermatol"},{"key":"R17-20250228","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1111\/j.1524-4725.2012.02582.x","article-title":"OnabotulinumtoxinA: a meta-analysis of duration of effect in the treatment of glabellar lines","volume":"38","author":"Glogau","year":"2012","journal-title":"Dermatol Surg"},{"key":"R18-20250228","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/asj\/sjac157","article-title":"Safety, pharmacodynamic response, and treatment satisfaction with onabotulinumtoxinA 40 U, 60 U, and 80 U in subjects with moderate to severe dynamic glabellar lines","volume":"42","author":"Joseph","year":"2022","journal-title":"Aesthet Surg J"},{"key":"R21-20250228","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/DSS.0000000000000757","article-title":"Duration of clinical efficacy of onabotulinumtoxinA in crow's feet lines: results from two multicenter, randomized, controlled trials","volume":"42","author":"Baumann","year":"2016","journal-title":"Dermatol Surg"},{"key":"R22-20250228","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1177\/0748806821989882","article-title":"Comparison of prabotulinumtoxin A to onabotulinumtoxin A in the treatment of lateral canthal rhytids: a side-by-side, randomized, double-blind comparison","volume":"38","author":"Brundridge","year":"2021","journal-title":"Am J Cosmet Surg"},{"key":"R23-20250228","first-page":"sjae131","article-title":"Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: results from the READY-1 double-blind, randomized, placebo-controlled Phase 3 trial in glabellar lines","author":"Shridharani","year":"2024","journal-title":"Aesthet Surg J"},{"key":"R26-20250228","doi-asserted-by":"crossref","first-page":"273","DOI":"10.2147\/CCID.S156851","article-title":"Botulinum neurotoxin formulations: overcoming the confusion","volume":"11","author":"Samizadeh","year":"2018","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"R27-20250228","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1097\/00042728-200305000-00002","article-title":"Development of the facial lines treatment satisfaction questionnaire and initial results for botulinum toxin type A-treated patients","volume":"29","author":"Cox","year":"2003","journal-title":"Dermatol Surg"},{"key":"R28-20250228","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1097\/DSS.0000000000000128","article-title":"Efficacy and safety of onabotulinumtoxinA for the treatment of crows feet lines: a multicenter, randomized, controlled trial","volume":"40","author":"Carruthers","year":"2014","journal-title":"Dermatol Surg"},{"issue":"S1","key":"R29-20250228","first-page":"E32496","article-title":"Treatment of crow's feet lines and forehead lines with Botox (onabotulinumtoxinA): development, insights, and impact","volume":"102","author":"Carruthers","year":"2023","journal-title":"Medicine (United States)"},{"key":"R32-20250228","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/BF00332351","article-title":"Significance of the LD50-test for the toxicological evaluation of chemical substances","volume":"47","author":"Zbinden","year":"1981","journal-title":"Arch Toxicol"},{"key":"R33-20250228","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5603\/PJNNS.a2021.0027","article-title":"Botulinum toxin type-A preparations are not the same medications - basic science (Part 1)","volume":"55","author":"Car","year":"2021","journal-title":"Neurol Neurochir Pol"},{"key":"R34-20250228","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1111\/jocd.16359","article-title":"Ready-to-use abobotulinumtoxinA solution versus powder botulinumtoxinA for treatment of glabellar lines: investigators' and subjects' experience in a Phase IV study","volume":"23","author":"Chadha","year":"2024","journal-title":"J Cosmet Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,28]],"date-time":"2025-02-28T13:11:54Z","timestamp":1740748314000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000004470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,18]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000004470","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,18]]}}}